FDA Approves Drug to Reduce Accidental Food Allergies FDA Approves Drug to Reduce Accidental Food Allergies
The new indication makes Xolair (omalizumab) the first drug approved to mitigate allergic reactions to more than one food.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology Source Type: news
Improve Your Dx of This Oft-Missed Genital Disorder Improve Your Dx of This Oft-Missed Genital Disorder
The nonspecific symptoms of lichen sclerosus often lead to a missed or delayed diagnosis, exacerbating the challenges that patients with the condition face.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Source Type: news
Tapinarof Under FDA Review for Treating Atopic Dermatitis Tapinarof Under FDA Review for Treating Atopic Dermatitis
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Exclusive-Wegovy Fuels Sharp Rise in Use Of Weight-loss Drugs for US Youth Exclusive-Wegovy Fuels Sharp Rise in Use Of Weight-loss Drugs for US Youth
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk ' s<NOVOb.CO> weight-loss drug Wegovy last year, a powerful new tool to address...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 15, 2024 Category: Allergy & Immunology Tags: Diabetes & Endocrinology Source Type: news
Eosinophilic Esophagitis: 5 Things to Know Eosinophilic Esophagitis: 5 Things to Know
Although delayed diagnosis of EoE presents considerable risk to those with this chronic inflammatory disease, novel treatments are providing hope that a new era is on the horizon.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 15, 2024 Category: Allergy & Immunology Tags: Gastroenterology Source Type: news
It's Risky to Mix Paxlovid With Immunosuppressants It's Risky to Mix Paxlovid With Immunosuppressants
The EMA has warned that Paxlovid should only be administered alongside tacrolimus, ciclosporin, everolimus, or sirolimus if their blood levels can be closely monitored.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Pharmacist Source Type: news
Lab Testing in Patients on Immunomodulators Falls Short Lab Testing in Patients on Immunomodulators Falls Short
Review found that fewer than 60% of patients with chronic inflammatory skin diseases underwent recommended testing before starting systemic immunomodulator treatment.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Immune Response May Cause Virus-Induced Neurologic Damage Immune Response May Cause Virus-Induced Neurologic Damage
Results from a mouse model could lead to the development of therapies to prevent neurologic damage caused by viruses such as Zika.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Neurology & Neurosurgery Source Type: news
Tinea Capitis Management in Kids Varies, Survey Finds Tinea Capitis Management in Kids Varies, Survey Finds
Respondents included 56 members of the Pediatric Dermatology Research Alliance.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Can Iron Supplementation Protect Against Celiac Disease? Can Iron Supplementation Protect Against Celiac Disease?
Genetically lower iron levels were associated with an increased risk for celiac disease in a Mendelian randomization study.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 13, 2024 Category: Allergy & Immunology Tags: Gastroenterology Source Type: news
FDA OKs First Oral Agent for Eosinophilic Esophagitis FDA OKs First Oral Agent for Eosinophilic Esophagitis
Budesonide oral suspension is indicated for 12 weeks of treatment of EoE in adults and children as young as 11 years.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 12, 2024 Category: Allergy & Immunology Tags: Gastroenterology Source Type: news
New Malaria Vaccine Proven Effective in Phase 3 Study New Malaria Vaccine Proven Effective in Phase 3 Study
The vaccine protected children under the age of 1.5 years against infection with an efficacy of 68%-75%.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 12, 2024 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
Analysis Finds Allergens in Many Topical Scar Products Analysis Finds Allergens in Many Topical Scar Products
Of the 156 products identified, most were gels, creams, or oils.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 10, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Patients With Stable Lupus May Be Safely Weaned Off MMF Patients With Stable Lupus May Be Safely Weaned Off MMF
Rates of significant disease reactivation were similar more than 1 year after randomization for patients assigned to mycophenolate mofetil (MMF) withdrawal or MMF maintenance.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 7, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis
The small-molecule oral investigational agent JNJ-77242113 at the highest dose tested was associated with reductions in psoriasis severity comparable to injectable biologic agents.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 7, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
